Background. End-stage renal disease care requires enormous economic resources. A timely dialysis start could reduce the costs of the renal replacement therapy (RRT). Our aim was to measure the time to dialysis in CKD patients, with an estimated glomerular filtration rate (eGFR) ≤11.0 ml/min/1.73 m 2 (MDRD derived), and to evaluate the safety, economic impact and the quality of life (QoL). Methods. In a prospective, observational study, 70 consecutive CKD patients, stage 5, were screened and 30 patients were selected and followed up monthly, for 24 months or until the start of RRT, set at an eGFR = 6.0 ml/min/ 1.73 m 2 or at the occurrence of pre-defined urgent criteria. The SF-36 questionnaire to evaluate the QoL was performed at the first and the last visit. Results. The median time to the start of dialysis was 11.8 (25th and 75th: 5.5-17.3) months. Only seven patients urgently started dialysis, after 8 months (25th and 75th: 4.8-20). The mean monthly cost of care was € 1146 ± 917 per patient. The QoL was similar to that of the general population and did not change at the last assessment. Discussion. This is the first study evaluating the economic impact of intensive conservative management of CKD stage 5 to postpone start of dialysis in tertiary care. This strategy allows us to safely gain a significant amount of time free from dialysis, with good QoL and major savings in the costs of nation's dialysis budget. The present results, however, are applicable only to low comorbidity patients referred to nephrology care and may not be generalized to all patients starting RRT.
Introduction
The number of patients with chronic kidney disease (CKD) who reach end-stage renal disease (ESRD) is increasing worldwide. The prevalence of CKD (stages [1] [2] [3] [4] in the USA increased from 10% to 13% in the decade 1994-2004, with 472 000 prevalent patients treated by dialysis and transplantation (ESRD) in 2006 [1] . Also in Italy, CKD affects a significant proportion of the general population, especially among the elderly [2] . It is estimated that more than 300 patients per million population (pmp) have a diagnosis of CKD each year and about 804 patients pmp are on chronic renal replacement therapy (RRT) [3] .
ESRD care requires a great amount of economic and human resources, and its growing cost derives from the greater number of patients rather than an increase in dialysis cost [4] . ESRD expenditure represents, in the USA, 6 .7% of the total Medicare budget [1] . In Italy, chronic dialysis consumes 2% of the total health expenditure every year [5] . In the near future, the number of patients with ESRD is expected to rise, mainly because of the increased longevity of the population. It is conceivable, therefore, that in the next decade, the RRT's costs will become unbearable and will eventually limit access to dialysis, as already happens in developing countries.
In this context, the issue of an appropriate start of RRT is of paramount importance, considering the huge amount of resources that can be saved by postponing start of dialysis. It is our opinion that all the measures that are safe and that may delay initiation of dialysis whilst ensuring that the patients remain healthy and are not at any increased risk should be taken. The optimum timing of dialysis treatment, however, is still a matter of debate, and is mainly based on clinical judgment and clinical experience. K/DOQI guidelines suggest that the estimation of glomerular filtration rate (eGFR) in conjunction with the evaluation of the nutritional and clinical status of the patient should guide decision making regarding dialysis initiation [6] . A prospective, multicentre, randomized, controlled trial has been designed to compare several outcomes in patients starting dialysis therapy with a Cockcroft-Gault GFR of 10.0-14.0 versus 5.0-7.0 ml/min/1.73 m 2 and the results are awaited [7] . Dialysis start at 6 ml/min/1.73 m 2 eGFR 3435
The aim of this study was to estimate the time to dialysis in stable CKD patients, stage 5, followed up in tertiary care. The patients satisfying the inclusion criteria for low comorbidity entered the study at an eGFR ≤ 11.0 ml/ min/1.73 m 2 and were followed up until the start of RRT, that was set at an eGFR = 6.0 ml/min/1.73 m 2 or at the occurrence of pre-specified events that were representative of uraemic complications and reflected the eventually declining health of the patients. The safety, the economic impact and the quality of life (QoL) of patients were evaluated.
Subjects and methods
The present study had a prospective, observational design and was conducted in the CKD out-patients clinic of the Nephrology Division at the University 'Federico II' of Naples, Italy. The recruitment time was 18 months, starting from 1 January 2005, and patients were followed up from 1 January 2005 to 1 August 2007. Consecutive patients with a creatinine clearance <15.0 ml/min/1.73 m 2 were considered for the study. Seventy patients were screened and 30 of them, 18 males and 12 females, were enrolled in the study and followed up for a maximum of 24 months (range: 2.5-24 months). The primary outcome of the study was the time (in months) to RRT. The study was approved by the local medical ethics committee.
The inclusion criteria were the following: a written informed consent, age >18 years, eGFR ≤11.0 ml/min/1.73 m 2 . The exclusion criteria were the inability to perform a 24-h urinary collection, malignancies, pregnancy, breast feeding, systemic diseases treated with steroids or immunosuppressive drugs, non-steroidal anti-inflammatory drugs given more than once in a week, dilatative cardiomyopathy, congestive heart failure (NYHA III-IV), type I and II diabetes mellitus and proteinuria >5 g/24 h.
GFR was estimated either with the MDRD-derived equation, including demographic and serum variables [8] , or with the arithmetic mean of the 24-h urea and creatinine clearances, corrected for body surface area [9] . MDRD eGFR has several limitations, including the variability of non-standardized serum creatinine dosage; however, since it is easy to perform and spread worldwide, we adopted this method for the purpose of the study. The two GFR measurements (Table 1) were correlated in our data series (Pearson's coefficient = 0.72, P <0.001). The values of eGFR were confirmed twice, either before entering the study (during the run-in period) or before starting dialysis. A variation of 10% above or below the initial data was allowed. The two levels of eGFR (11.0 ml/min/1.73 m 2 and 6.0 ml/min/1.73 m 2 ) were, respectively, chosen for entering the study and for starting RRT, and were derived from the published guidelines [6, 10] .
Forty patients were excluded at the screening (Table 1) for the following reasons: 5 for inability to perform a reliable 24-h urinary collection, 9 for an eGFR ≤ 6 ml/min/1.73 m 2 , 8 for diabetes, 1 for malignancy, 5 for systemic diseases treated with immunosuppressive drugs, 1 for congestive heart failure, 1 for proteinuria >5 g/24 h, 2 died before completing the screening, 1 needed urgent HD treatment for uaremic haemolytic syndrome, 4 refused the study and 3 were not compliant to the run-in scheduled visits.
The included patients were extensively informed of the dialysis modalities [peritoneal dialysis (PD) and haemodialysis (HD)], and those choosing HD were encouraged to undergo surgery for the vascular access, if not already present. After the enrolment, the patients were prescribed a low protein diet [0.6 g/kg ideal body weight (IBW)/day] [11, 12] . The details of the diet have been previously reported [13] and included the prescription of aproteic special products; three patients did not use such products. Dietary protein intake (DPI) was estimated in stable, non-catabolic condition, according to the Maroni formula [14] . Protein-caloric malnutrition was defined as the occurrence of one of the following: loss of body weight >5% in 1 month or 10% in 3 months or BMI <20 kg/m 2 with serum albumin <3.2 g/dl and normal values of C-reactive protein (CRP) <0.5 mg/dl. During 1-month run-in period, eGFR was confirmed, patients were trained to comply with the diet and the achievement of therapeutic targets was applied. Verification of the dietary adherence was accomplished by an expert renal dietitian every other month. After 1 month, the patients underwent the first clinical visit, referred to as 'baseline visit'. Demographic and clinical data were obtained at baseline, for the included patients, and at screening for those who were excluded. Primary kidney diseases were classified according to the European Renal Association codes. Comorbidity was assessed using the Charlson comorbidity index score [15] . At baseline and in each month, we performed a complete clinical evaluation, and recorded the therapy, cardiovascular (CV) events and hospitalizations. The following blood chemistries were measured monthly, in the central laboratory of our institution: urea nitrogen, creatinine, bicarbonate, sodium, potassium, phosphate, calcium, intact parathyroid hormone (iPTH), total proteins, albumin (Bromo Cresol Purple method; normal range: 3.5-4.8 g/dl), total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, uric acid, haemoglobin, total iron binding capacity (TIBC), iron, CRP, fibrinogen and homocysteine. Urea nitrogen, creatinine, sodium, potassium, phosphate, and proteins were measured in the 24-h urinary collection. The patients were instructed about the study procedures and how to obtain a careful urinary collection. Standard laboratory procedures were used for blood and urinary measurements. At the first and last check-up, bioelectrical impedance analysis (B.I.A.) and SF-36 questionnaire were performed [16] . Chest x-ray, ECG and echocardiography were performed every 6 months or before reaching the end point. Echocardiography was done by the same operator using an ultrasound system (Sonos 2000, Hewlett-Packard, Andover, MA, USA) equipped with a 2.5-MHz transducer. Left ventricular mass (LVM) was calculated by the Penn Convention formula [17] . The LVM index was obtained dividing LVM by the body surface area. The SF-36 questionnaire, recently validated in Italy [18] , assesses eight dimensions of health-related QoL (HRQoL) that refer to the physical and mental components of health perception. Physical functioning (PF), role-physical (RP) and bodily pain (BP) are more related to the physical component; social functioning (SF), roleemotional (RE) and mental health (MH) are more related to the mental component, and energy/vitality (VT) and general health (GH) are related to both components [16] . These global measures were estimated using standard algorithms [19] .
A cost-of-treatment analysis was performed. Direct medical costs, financed by the National Health Service (NHS), which in Italy provides health care services to patients with advanced CKD, were calculated by multiplying resources absorbed by their unit cost. They included the cost of therapies, hospitalizations, laboratory, diagnostic examinations, surgery, rehabilitation procedures, physicians' visits and any other possible cost, including the aproteic foodstuff. The cost of medical services [20] was estimated using the Italian NHS tariffs, hospital costs were computed applying Diagnosis Related Group [21] and charges and drug therapies were quantified using market prices reported by the Italian National Therapeutic Formulary (Italian Directory of Medicines and Manufacturers 2008). The cost of aproteic products (Plasmon Dietetici Alimentari S.r.l. Milano, Italy) was calculated on the basis of the reimbursement that the local government (Regione Campania) recognized to the seller, at the time of the study period. All costs were expressed in Euro format and were computed as Euro per patient per month.
We used pharmacological and non-pharmacological therapies to achieve the therapeutic targets that were in keeping with the current clinical practice guidelines. The target blood pressure (BPr) was <130/80 mmHg [22] . All classes of antihypertensive drugs were used. The range of PTH levels was between 150 and 300 pg/ml; hyperparathyroidism was treated by calcitriol (1.25 dihydroxycholecalciferol); the serum calcium level ranged between 8.4 and 9.5 mg/dl and the serum phosphate level between 3.5 and 5.5 mg/dl [23] . Hyperphosphataemia was treated by calcium carbonate (0.2-0.5 g/meal up to a maximum of 2 g/day) or sevelamer (3.2-10 g/day) if needed. The patients with low serum calcium levels (<8.4 mg/dl) were treated by calcium supplements and/or calcitriol. Serum bicarbonate levels were aimed at 22 mEq/l or above [23] , and oral supplements of sodium bicarbonate were prescribed [24] . Lipid levels were treated by dietary modification and/or medications to achieve a target non-HDL cholesterol (total cholesterol minus HDL) <130 mg/dl, LDL cholesterol <100 mg/dl and triglycerides <200 mg/dl [25] . The haemoglobin target was between 11.0 and 12.0 g/dl for both men and women according to the indications of K/DOQI [26] .
The patients ended the study if they registered and confirmed an eGFR = 6.0 ml/min/1.73 m 2 or reached 24 months of follow-up or met one of the following criteria for RRT: (1) wKt/V urea <2 associated with a normalized protein nitrogen appearance (nPNA) <0.6 g/kg/day or reduction of body weight >5%/month or >10% in 3 months; (2) serum albumin <3.3 g/dl; (3) serum urea ≥2.5 g/l (with wKt/V urea >2); (4) dyspnoea on exertion with Hb >10.5 g/dl; (5) oedema resistant to diuretics (in the absence of therapy with calcium channel blockers and with a pathologic echocardiography); (6) serum potassium >6.5 mEq/l resistant to therapies; (7) pericardial effusion and/or atrial or ventricular dilatation; (8) and (9) uraemic symptoms (anorexia, nausea and vomiting in the presence of metabolic acidosis treated with sodium bicarbonate). Death and kidney transplant were considered end-points of the study.
Statistical methods
All the laboratory and clinical data were checked for normal distribution (Shapiro-Wilk test), and mean ± SD or median with 25th and 75th percentiles were used if data had normal or skewed distribution, respectively. The paired samples t-test, Fisher's exact test, Wilcoxon signed-rank test and McNemar's test were used as appropriate. The Kaplan-Meier method was chosen to represent the time to the end of the follow-up, due to event occurring (starting dialysis or death) or the reaching of the 24th month. Analyses were considered significant at P-value < 0.05. Analyses were performed using STATA 9.2 SE (Stata Corp., College Station, TX, USA). Table 1 shows the clinical characteristics of the screened population. The patients who matched the inclusion criteria, as compared to those who were excluded, were slightly younger, had similar renal diseases, except for diabetes and unknown causes, and comparable mean eGFR and urea Kt/V. The included subjects had a significantly lower Charlson's comorbidity index, with an average score of 3.9 ± 1.22 as compared to 5.2 ± 2.0 (P < 0.05) and a higher frequency of peripheral vascular diseases (P < 0.05). The renal survival of the studied patients is shown in Figure 1 . The median time to dialysis start was 11.8 months (5.4-17.3).
Results
Eight patients (27%) ended the study without starting dialy- sis after 21.8 months (16.6-24.5); 14 patients (47%) started dialysis because their eGFR reached 6.0 ml/min/1.73 m 2 after 8.8 months (4.9-11.8); 7 subjects (23%) started dialysis due to the occurrence of one of the pre-defined criteria after 8 months (4.8-20.0) and with an eGFR = 7.9 ± 1.3 ml/min/1.73 m 2 ; 1 patient withdrew his informed consent after 8 months for difficulty in attending the monthly visits. None of the patients died during the follow-up, and all of them were still alive 12 months after the end of the followup period (31 August 2008). Table 2 shows initial and final nutritional data. These indexes were generally within normal limits in all patients at the end of the study and similar to the initial values, such as the mean body weight, serum albumin, bicarbonate levels, TIBC, CRP, urinary urea nitrogen and urinary sodium. There was a significant difference between initial and final values for median protein intake that decreased from 1.0 g/kg IBW/day (0.97-1.08) to 0.67 (0.60-0.90) (P < 0.05) and for serum urea nitrogen that increased on the average of 15 mg/dl. Nineteen patients had an average protein intake between 0.50 and 0.80 g/kg IBW/day, and the remaining 11 patients had an intake between 0.81 and 1.50 g/kg IBW/day. None of the patients registered a reduction of albumin or a weight loss that reached the pre-defined malnutrition criteria. Table 3 shows the initial and final clinical and metabolic parameters with the LVM data. At baseline, 57% and 77% of patients achieved targets for SBPr and DBPr, respectively. At the end of the follow-up, 63% and 67% of patients achieved the same targets. The LVM index did not significantly increase during the observation period. Among males, 1/18 patients at the start and 2/18 at the end had a LVM >130 g/m 2 . Among females, 9/12 at the start and 8/12 at the end of the follow-up had a LVM >110 g/m 2 . Fifty percent of patients were on target for non-HDL cholesterol at baseline and 77% at the end, with 40% of patients achieving LDL target at the start and 67% at the end of the study (P < 0.05); 90% were on target at baseline for triglycerides, and all the patients achieved the target at the end of the follow-up (P < 0.05). Eighty-three percent of patients had haemoglobin levels >11 g/dl at baseline and 77% at the end of the study; among these patients, 7 (28%) at baseline and 14 (61%) at the end were treated with erythropoiesisstimulating agents (ESA). Eighty percent of patients at baseline and 73% at the end of study had a percentage of transferrin saturation >20%. Seventy-three percent of patients at baseline and 60% at the end of follow-up were on target for iPTH levels (<300 pg/ml); seven patients at the end of follow-up had an iPTH between 450 and 900 pg/ml, two of whom had a baseline iPTH >300 pg/ml; 93% of patients at baseline and 97% at the end of the study were on target for serum calcium levels; 93% at baseline and 80% at the end of the study achieved serum phosphate target, with final levels significantly higher than initial values. At baseline, 27% of patients achieved all the targets for PTH, calcium, phosphorus and calcium-phosphorus product at the same time. At the end of the study, 17% of patients achieved the same goal. The average monthly cost of care was €1146 ± 917 per patient, mainly because of hospitalization that represented 42% of the expenses (Table 4) . During the study, a total of 27 hospitalizations occurred (three patients needed 2 hospitalizations each), with a median length of 5 days (2.0-9.0). In 22 cases, the main reason for hospitalization was vascular access surgery and/or the first 23 dialysis sessions; in one patient a catheter for PD was inserted; two patients needed a central venous catheter for urgent start of dialysis after 5 and 8 months of follow-up, respectively. They also underwent surgery for the artero-venous fistula that they had previously refused; five patients were hospitalized for other causes (hyponatraemia, hypotension and cranial trauma, hydrocephalus, worsening of renal function and pulmonary pre-oedema).
SF-36 was administered at baseline and at the end of the study, evaluating eight dimensions of QoL. All the components were similar at the start as well as at the end of the follow-up, thus SF-36 results showed QoL stable during the observation period and quite similar to that of the general population [18] (Figure 2 ).
Discussion
A wide range of GFR values are used in clinical practice to support dialysis, and this interval may correspond to several months, if not years, free of RRT. The timing of dialysis start represents a complex clinical decision, that beyond the estimate of GFR, has to take into account several components, such as the patient's well-being and QoL, the risks related to the delaying of the therapy and the patients' exposure to the unpleasant experience of dialysis. A substantial costs reduction could be attainable by starting dialysis at an eGFR of 6.0 ml/min/1.73 m 2 ; nevertheless, it is fundamental to guarantee an optimal metabolic and clinical status to the patients waiting a timely start of RRT.
The median time to dialysis from an eGFR ≤11.0 ml/ min/1.73 m 2 was 11.8 months. During this time, the majority of patients did not present relevant clinical problems or any other conditions that are traditionally considered as indicators for the initiation of dialysis. Only 23% [7] of subjects needed to start RRT because of the occurrence of at least one of the pre-defined criteria. Comparing these data with those obtained from the excluded patients, it is evident that the higher comorbidity was the major determinant for the start of dialysis. In fact, the median time to dialysis of this group of patients was of 4.0 months (2.0-6.0), with a mean eGFR of 7.0 ± 2.4 ml/min/1.73 m 2 . At 31 August 2008 (12 months after the end of the follow-up), 31 patients were alive after 37.5 months (28.0-40.0) of dialysis, 3 of them received a kidney transplant and 1 did not start RRT.
There were no signs of malnutrition in any of the patients studied, even in those who started dialysis because of uraemic symptoms, and none of the patients complained anorexia or loss of appetite. Moreover, albumin levels were always >3.5 g/dl. Only two patients had albumin levels between 3.2 and 3.5 g/dl during the observation; both had a proteinuria of 4-5 g/24 h, without signs of inflammation.
The majority (63%) of patients studied were able to comply with the dietary recommendations of KDOQI guidelines [11] that suggest a protein content of the diet between 0.6 and 0.8 g/kg IBW/day. The compliance with such a diet is not hard to obtain, especially with the help of a renal dietitian, and can be reached even without the use of aproteic special products. A low protein diet, even if does not play a major role in retarding the progression of renal diseases, is able to guarantee a good metabolic control of renal failure [13] and, therefore, may be useful in delaying the start of RRT.
Hypertension control is one of the main aims of delaying the progression of renal disease as well as reducing cardiovascular risk of CKD. We obtained a good control for the SBPr (∼60% of patients) as well as for the DBPr (∼70% of patients). A high prevalence of hypertension in CKD as well as in dialysis patients has been described. The TABLE study, that focuses on the prevalence of CV determinant risks in pre-dialysis patients in Italy, described a poor hypertension control with only 12% of patients, CKD stage 5, reaching BPr <130/80 mmHg [27] . In HD patients, a prevalence of hypertension of 70-80% and a proportion of adequately treated patients of 30% have been described [28] . A recent retrospective study showed that hypertension in CKD patients, before starting HD, is a major risk factor for CV mortality during HD [29] , emphasizing the importance of an early and adequate control of BPr in this population. This strategy is important also for the prevention of left ventricular hypertrophy (LVH) that has been found in 65% of CKD patients [27] and in 70-80% of the patients starting HD [30] . LVM is an independent predictor of CV disease and a mortality risk factor in the general population as well as in dialysis patients [31] . In our study, LVM did not significantly increase during the follow-up; 94% of male patients at the start and 88% at the end of the observation had a normal LVM value, while the majority of females (∼70%) were hypertrophic from the beginning. A sex dimorphism in the prevalence of LVH has been suggested in the general population, and also in dialysis patients [32] . Another modifiable CV risk factor in CKD is anaemia. Eighty percent of our patients had haemoglobin levels >11 g/dl at the end of the follow-up, while the prevalence of anaemia has been reported to be of 50% in CKD patients, stage 5, treated with ESA [27] . Concerning mineral metabolism, only a small minority of patients meet all guidelines for phosphorus, calcium and PTH [33] . In our study, only seven patients had iPTH levels >450 pg/ml at the end of the observation. From the clinical point of view, our patients started RRT and/or ended the study in quite optimal clinical conditions, even though some of these patients did not have a nephrology follow-up prior to the entry of the study.
To our knowledge, this is the first study, in Italy, evaluating the economic impact of intensive conservative management of CKD stage 5, to postpone start of dialysis. This treatment strategy, with an average monthly cost of care of ∼1146 Euro per patient, seems to be less costly than dialysis treatment, which amounts to more than 3000 Euro per patient per month [34] . Dialysis, in fact, exposes patients to several diagnostic and therapeutic procedures that represent an additional burden and also an additional cost for the patients and the National Health Service, thereby influencing lifestyle and possibly affecting HRQoL. Considering also indirect costs, delaying HD will reduce the burden of moving frequently to and from the hospital, as well as the time consumed during the dialysis treatment. The present data provide evidence that conservative strategy has a positive effect on HRQoL, which remained stable during the followup with no statistical differences in any of the domains after 2 years of the treatment period. The QoL of these patients, in fact, is comparable to that of the general population [18] and better than the dialysis population [35] . In general, the patients studied seem to perceive a better health state than patients on RRT, especially in the BP domain. Dialysis, as an invasive intervention, in fact reduces individual physical performance, capability to work and social integration and it often requires family engagement.
It is important to underscore that this is an observational study, with all the limitations of that study design; furthermore, the present results are applicable to nondiabetic low comorbidity patients and may not be generalized to all patients starting RRT, and even with this limitation, some patients need to anticipate dialysis start. Our data, however, are in agreement with recent findings showing that, in a large cohort of CKD patients followed up in a nephrology care unit, 37% of patients with an eGFR <15.0 ml/min/1.73 m 2 after 2 years of follow-up did not reach the outcomes of either dialysis therapy or death [36] . These results, taken together, are of great relevance in planning health care resources and for the allocation of funding for CKD programmes.
In conclusion, our data show that for a consistent number of patients waiting to initiate dialysis, under nephrology care, it is safe to use 6.0 ml/min/1.73 m 2 eGFR as a dialysis start. This means that patients, within CKD stage 5, may gain years free from dialysis, with good QoL and major savings for the costs of the nation's dialysis budget. However, patients need a close follow-up, with monthly checks, and it is low comorbidity patients who benefit the most from this therapeutic strategy.
